DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer
DelMar Pharmaceuticals, Inc.(OTCQB: DMPI) ("DelMar" “the company”) announced today a protocol amendment to allow for expanded dosing in its VAL-083 clinical trial had been filed with the U.S. Food and Drug Administration (FDA) and that a new cohort of a new 50mg/m2 has been opened at three clinical trial sites in the United States. The company also confirmed that gross proceeds of US$2.9 million have been raised through warrant exercise in two separate closings. These funds provide sufficient working capital...
View full press release